What BMI Do You Need for Wegovy in the UK?

Short answer: under current NICE guidance, adults may be eligible for Wegovy (semaglutide) through an NHS specialist weight-management service if their BMI is generally at least 35 kg/m² and they have at least one weight-related condition. People with a BMI of 30 to under 35 may also qualify if they meet the criteria for referral to that specialist service. Lower BMI thresholds apply to some ethnic groups.

Meeting the BMI threshold does not guarantee a prescription. A clinician will consider your health, previous support, suitability for treatment, and whether a service is available. Wegovy should be used alongside a reduced-calorie diet and increased physical activity—not as a stand-alone shortcut to weight loss.

NICE criteria for Wegovy in England

NICE recommends semaglutide for weight management in adults when it is prescribed as part of a specialist weight-management service. The main BMI thresholds are:

BMI What NICE guidance generally requires 35 kg/m² or higher At least one weight-related condition, such as high blood pressure, abnormal cholesterol, obstructive sleep apnea, cardiovascular disease, or type 2 diabetes. 30 to under 35 kg/m² Eligibility for referral to a specialist, multidisciplinary weight-management service.

For people from some ethnic semaglutide for weight loss backgrounds—including South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds—NICE advises using BMI thresholds reduced by 2.5 kg/m². This reflects evidence that some groups may experience weight-related health risks at a lower BMI. A clinician can explain how the adjustment applies to your circumstances.

These are the broad NICE criteria, not a substitute for an individual assessment. NHS commissioning arrangements and access can vary, and services may have additional referral or capacity requirements. The NICE recommendation is for treatment through a specialist service, typically one that can provide support from a multidisciplinary team. It is not simply a rule that anyone above a particular BMI can request a prescription from any provider.

What counts as a weight-related condition?

A weight-related condition is a health problem that is associated with excess weight and may affect the risks and benefits of treatment. Examples include:

High blood pressure or abnormal blood lipids, such as raised cholesterol.
Type 2 diabetes or prediabetes.
Obstructive sleep apnea.
Cardiovascular disease.
Other conditions identified by a clinician as relevant to your weight and health.

Your healthcare professional will assess your medical history rather than relying only on a list. BMI is a screening measure; it does not directly measure body fat, muscle mass, or where weight is carried. It is one part of a broader discussion about health and treatment options.

What is a specialist service?

NICE’s recommendation places Wegovy within a specialist weight-management service. In practice, this means treatment is supported by clinicians who can assess whether the medicine is suitable, help you work through dose changes, and provide ongoing advice about nutrition, activity, and health monitoring. Access pathways differ across the UK, so ask your GP or local NHS service what is available in your area.

NICE recommends treatment for a maximum of two years under its guidance. The service should consider stopping semaglutide if an adult has not lost at least 5% of their initial body weight after six months on the highest tolerated dose. This is a review point, not a promise that everyone will lose that amount. Continued treatment should be based on progress, tolerability, and clinical judgment.

How GLP-1 receptor agonists work

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It acts on pathways involved in appetite and blood glucose regulation. In many people, it helps reduce hunger, increases feelings of fullness, and makes it easier to eat smaller portions. Pretty simple.. It can also slow stomach emptying, particularly during the early stages of treatment.

Wegovy is the brand of semaglutide used for weight management, at a dose and treatment schedule intended for that purpose. Ozempic also contains semaglutide, but it is a different branded product prescribed for type 2 diabetes. The two brands should not be treated as interchangeable: the approved indication, dose, and prescribing context differ. Do not switch products or change a dose without advice from your prescriber.

Semaglutide is usually introduced gradually, with dose increases over time to help the body adjust. This reminds me of something that happened was shocked by the final bill.. A clinician may delay an increase or review treatment if side effects are difficult to manage. It works best as one element of a broader plan that supports sustainable eating, movement, sleep, and health habits.

What do the STEP trials and other RCTs show?

The STEP program studied semaglutide for weight management in randomized controlled trials (RCTs). In STEP 1, adults with overweight or obesity without diabetes received semaglutide 2.4 mg or placebo alongside lifestyle support. At 68 weeks, average weight change was about 14.9% in the semaglutide group and 2.4% in the placebo group. These are group averages; individual results varied, and trial participants received structured support.

STEP 4 examined what happened after an initial period of semaglutide treatment. Participants who continued the medicine generally maintained or increased their weight loss, while those switched to placebo regained weight on average. This illustrates an important point: for some people, obesity is a long-term condition, and stopping treatment may lead to appetite and weight changes. It does not establish what will happen to every person after stopping.

Other RCTs, including studies in people with type 2 diabetes, also found meaningful average weight reductions, although results differed by population and study design. Trial evidence supports semaglutide as an effective option for many eligible adults, but it cannot predict an individual’s response or replace medical assessment. The medicine’s benefits must be weighed against side effects, health history, preferences, and the likelihood of continued access and follow-up.

Side effects and safety monitoring

The most common side effects are gastrointestinal. They often occur during dose increases and may improve over time, but they can be persistent or severe for some people.

Nausea, vomiting, diarrhea, or constipation.
Abdominal discomfort, bloating, or indigestion.
Reduced appetite and, sometimes, headache or fatigue.

Speak with your prescriber if symptoms are severe, do not settle, or make it difficult to eat or drink. Ongoing vomiting or diarrhea can cause dehydration. Seek urgent medical advice for severe, persistent abdominal pain, particularly if it spreads to the back or occurs with vomiting. Your clinician can advise on other warning signs and what to do.

Before treatment, discuss your medical history, current medicines, allergies, and any planned pregnancy. Semaglutide is not suitable for everyone. A prescriber may need to consider issues such as diabetes medicines that can cause low blood sugar, previous pancreatitis, gallbladder problems, or other conditions. Do not start, stop, or adjust prescription medicines on your own.

Monitoring may include checking weight and treatment response, reviewing side effects and hydration, and considering relevant health measures such as blood pressure or blood glucose. The schedule depends on your clinical situation and local service. If you have diabetes, your diabetes team may need to review your glucose-lowering treatment as your eating habits or weight change.

Can you get Wegovy privately?

I'll be honest with you: some regulated private providers may prescribe semaglutide after a proper clinical assessment. Private prescribing is not the same as NHS eligibility: a provider should check your BMI, health history, medicines, and suitability, and should arrange appropriate follow-up. Rules and services can change, so confirm that a provider is properly regulated and that the product is supplied through a legitimate pharmacy.

Be cautious about buying weight-loss injections through online marketplaces or social media channels. A product may be counterfeit, improperly stored, the wrong strength, or supplied without a valid prescription and clinical assessment. Photos, testimonials, and claims of “quick fixes” are not evidence that a medicine is genuine or safe. Avoid products offered without a prescription or from sellers whose credentials and supply chain cannot be verified.

Questions to ask your GP or specialist

Does my BMI meet the relevant NICE criteria, including any ethnic-adjustment threshold?
Do I have a weight-related condition that affects my eligibility or treatment options?
Can I be referred to a specialist service, and what support does it provide?
How will side effects and progress be monitored, and when will treatment be reviewed?
What alternatives are available if Wegovy is unsuitable, unavailable, or does not work well for me?

The bottom line

For NHS treatment in England, NICE’s usual Wegovy criteria are a BMI of at least 35 kg/m² plus at least one weight-related condition, or a BMI of 30 to under 35 kg/m² with eligibility for a specialist weight-management service. Lower thresholds apply to certain ethnic groups. A specialist assessment, safe prescribing, and ongoing support matter just as much as the number on the BMI chart.

If you think you may qualify, speak with your GP or local weight-management service. They can explain referral routes, assess your health, and discuss whether semaglutide—or another approach—is appropriate for you. NICE recommendations and local access arrangements can change, so confirm current guidance with a qualified healthcare professional.